Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease
Autor: | Hiroshi Yamasaki, Masaru Morita, Hidetoshi Takedatsu, Shuhei Fukunaga, Keiichi Mitsuyama, Atsushi Mori, Toshihiro Araki, Ryosuke Sakemi, Shinichiro Yoshioka, Kozo Tsuruta, Takuji Torimura, Kotaro Kuwaki, Tetsuhiro Yoshimura |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Article Subject Immunology Disease Peripheral blood mononuclear cell Inflammatory bowel disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Crohn Disease Internal medicine Gene expression Pathology RB1-214 Medicine Humans Clinical significance Glycoproteins chemistry.chemical_classification business.industry Cell Biology Middle Aged medicine.disease Inflammatory Bowel Diseases Ulcerative colitis 030104 developmental biology C-Reactive Protein chemistry Cohort Leukocytes Mononuclear 030211 gastroenterology & hepatology Colitis Ulcerative Female business Glycoprotein Biomarkers Research Article |
Zdroj: | Mediators of Inflammation Mediators of Inflammation, Vol 2021 (2021) |
ISSN: | 1466-1861 |
Popis: | Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are scarce; the methods for estimating disease activity are less established, particularly for CD. This study is aimed at evaluating the utility of serum LRG as a potential inflammatory marker for IBD and to investigate the LRG gene expression in peripheral blood mononuclear cells (PBMCs) as a possible source of serum LRG. Overall, 98 patients with UC and 96 patients with CD were prospectively enrolled and clinically evaluated; 92 age-matched individuals served as the healthy controls. The blood samples were analyzed for serum LRG levels and routine laboratory parameters. Disease activity was assessed clinically and endoscopically. Finally, LRG gene expression in the PBMCs from a different cohort (41 patients with UC, 34 patients with CD, and 30 healthy controls) was examined. The serum LRG levels were higher during active disease than during inactive disease; additionally, serum LRG levels were positively correlated with clinical disease activity, C-reactive protein (CRP) levels, and other laboratory parameters in patients with UC and CD and with endoscopic disease activity in UC. UC and CD showed comparable areas under the curve (AUC) values for determining clinical remission and differentiating between endoscopic remission associated with LRG and CRP. The levels of LRG mRNA were also increased in PBMCs from patients with UC and CD and reflected disease activity. These data suggest that serum LRG, originated partially from PBMCs, is an inflammatory marker in UC and CD. A large-scale well-designed study should be conducted in the future to more accurately reveal the clinical significance of LRG in patients with IBD. |
Databáze: | OpenAIRE |
Externí odkaz: |